SEARCH

SEARCH BY CITATION

References

  • 1
    Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 2
    Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSida Study Group. Lancet 1998; 352: 17251730.
  • 3
    Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 14231430.
  • 4
    Hicks C, Currier J, Sax P, Sherer R, Wanke C. Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. AIDS Patient Care STDs 2003; 17: 221233.
  • 5
    Currier JS. Cardiovascular risk associated with HIV therapy. J Acquir Immune Defic Syndr 2002; 31: S16S32.
  • 6
    Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis 2003; 37: 959972.
  • 7
    Sklar P, Masur H. HIV infection and cardiovascular disease – Is there really a link? N Engl J Med 2003; 349: 20652067.
  • 8
    Santos J, Palacios R, González M, Ruiz J, Márquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar study). Int J STD AIDS 2005; 16: 677680.
  • 9
    Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving PI. AIDS 1998; 12: F51F58.
  • 10
    Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. A 5-year cohort study. Arch Intern Med 2000; 160: 20502056.
  • 11
    Palacios R, Santos J, Ruiz J, González M, Márquez M. Factors associated with the development of diabetes in HIV-infected patients on antiretroviral therapy: a case-control study. AIDS 2003; 17: 933935.
  • 12
    Mattana J, Siegal FP, Sankaran RT, Singhal PC. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci 1999; 317: 232237.
  • 13
    Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Codrobbi P. Indinavir and systemic hypertension. AIDS 2001; 15: 805807.
  • 14
    Sattler FR, Qian D, Louie S et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15: 20012010.
  • 15
    Hadigan C, Meigs J, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2003; 32: 130138.
  • 16
    Galindo Puerto MJ. Arterial hypertension and HIV – a new problem? Nutr Metab Disord HIV Infect 2002; 1: 3337.
  • 17
    Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 13771382.
  • 18
    Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian Study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22: 731736.
  • 19
    Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4: 411416.
  • 20
    Seaberg EC, Muñoz A, Lu M et al. HIV infection, HAART, and blood pressure: results from the Multi-center AIDS Cohort Study. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February, 2003 [Abstract 744].
  • 21
    Friis-Moller N, Weber R, Reiss P et al. (DAD Study Group). Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 11791193.
  • 22
    Joint National Committee. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 24132446.
  • 23
    Kannel WB, Vasan RS, Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension 2003; 42: 453456.
  • 24
    Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). J Am Med Assoc 2001; 285: 24862497.
  • 25
    Must A, Dallal GE, Dietz WH. Reference data for obesity: 85th and 95th percentiles of body mass index (wt/ht2) and triceps skin-fold thickness. Am J Clin Nutr 1991; 53: 839846.
  • 26
    Carr A. HIV protease inhibitor-induced lipodystrophy syndrome. AIDS Rev 1999; 1: 2936.
  • 27
    Banegas JR, Rodríguez-Artalejo F, De la Cruz Troca JJ, Guallar-Castillón P, del Rey Calero J. Blood pressure in Spain. Distribution, awareness, control and benefits of a reduction in average pressure. Hypertension 1998; 32: 9981002.
  • 28
    Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and United States. J Am Med Assoc 2003; 289: 23632369.
  • 29
    Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63F70.
  • 30
    Mulligan K, Grunfeld C, Tai WW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 3543.
  • 31
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 25702581.